Form 4: Cassava Sciences CFO Eric Schoen Reports Stock Option Grant

Eric Schoen, CFO of Cassava Sciences, reports the acquisition of stock options.

Summary

• Eric Schoen, the Chief Financial Officer of Cassava Sciences Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 20, 2024.
• Schoen acquired 25,000 stock options with an exercise price of $22.10.
• These options vest over four years, at a rate of 1/48th each full month, and expire on May 20, 2034.
• Following the reported transaction, Schoen directly owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also use stock options to incentivize their executives.
• The vesting schedule of four years is also typical in the industry.

Stakeholder Impact

• The stock option grant could potentially incentivize the CFO to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates